It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GRFS’s FA Score shows that 1 FA rating(s) are green whileSCLX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GRFS’s TA Score shows that 5 TA indicator(s) are bullish while SCLX’s TA Score has 5 bullish TA indicator(s).
GRFS (@Pharmaceuticals: Major) experienced а -0.21% price change this week, while SCLX (@Pharmaceuticals: Major) price change was -30.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.55%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was +2.00%.
GRFS is expected to report earnings on Feb 27, 2025.
SCLX is expected to report earnings on May 12, 2023.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
GRFS | SCLX | GRFS / SCLX | |
Capitalization | 5.48B | 166M | 3,299% |
EBITDA | 640M | -109.1M | -587% |
Gain YTD | -18.080 | -70.103 | 26% |
P/E Ratio | 68.68 | N/A | - |
Revenue | 6.54B | 46.7M | 13,994% |
Total Cash | 544M | 3.92M | 13,874% |
Total Debt | 11.1B | 128M | 8,672% |
GRFS | ||
---|---|---|
OUTLOOK RATING 1..100 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 83 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GRFS | SCLX | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago84% |
Stochastic ODDS (%) | 3 days ago72% | 3 days ago53% |
Momentum ODDS (%) | 3 days ago67% | 3 days ago41% |
MACD ODDS (%) | 3 days ago58% | 3 days ago40% |
TrendWeek ODDS (%) | 3 days ago72% | 3 days ago65% |
TrendMonth ODDS (%) | 3 days ago71% | 3 days ago82% |
Advances ODDS (%) | 25 days ago73% | 12 days ago65% |
Declines ODDS (%) | 5 days ago73% | 3 days ago86% |
BollingerBands ODDS (%) | 3 days ago77% | 3 days ago57% |
Aroon ODDS (%) | 3 days ago65% | 3 days ago20% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SBIDX | 9.97 | N/A | N/A |
Sterling Capital Behavioral Intl Eq C | |||
JSECX | 25.93 | -0.25 | -0.95% |
JPMorgan Small Cap Equity C | |||
IJSTX | 16.15 | -0.19 | -1.16% |
VY® JPMorgan Small Cap Core Equity S2 | |||
IRGFX | 22.86 | -0.39 | -1.68% |
Delaware Ivy Small Cap Growth R6 | |||
PHPSX | 22.05 | -0.91 | -3.96% |
ProFunds Pharmaceuticals UltraSector Svc |
A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.
Ticker / NAME | Correlation To GRFS | 1D Price Change % | ||
---|---|---|---|---|
GRFS | 100% | -0.84% | ||
GIKLY - GRFS | 68% Closely correlated | +0.80% | ||
GIFOF - GRFS | 37% Loosely correlated | N/A | ||
PFE - GRFS | 28% Poorly correlated | -4.69% | ||
GIFLF - GRFS | 23% Poorly correlated | N/A | ||
AMGN - GRFS | 21% Poorly correlated | -4.16% | ||
More |
A.I.dvisor tells us that SCLX and OGN have been poorly correlated (+13% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCLX and OGN's prices will move in lockstep.
Ticker / NAME | Correlation To SCLX | 1D Price Change % | ||
---|---|---|---|---|
SCLX | 100% | -10.31% | ||
OGN - SCLX | 13% Poorly correlated | -1.83% | ||
AMRN - SCLX | 11% Poorly correlated | -3.85% | ||
GRFS - SCLX | 10% Poorly correlated | -0.84% | ||
BIIB - SCLX | 10% Poorly correlated | -2.97% | ||
RHHVF - SCLX | 8% Poorly correlated | -3.12% | ||
More |